Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02306850
Title Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors St. Louis University
Indications

melanoma

Therapies

Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.